Kezar Life Sciences, Inc.
KZR
$6.04
-$0.01-0.17%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | 36.40% | 23.56% | 37.33% | 12.08% | 11.36% |
| Total Depreciation and Amortization | -6.90% | -3.46% | -7.50% | -6.47% | 4.82% |
| Total Amortization of Deferred Charges | -35.38% | 148.44% | 11.86% | 10.34% | 10.17% |
| Total Other Non-Cash Items | -43.48% | 8.85% | -47.78% | -59.78% | 47.43% |
| Change in Net Operating Assets | -228.04% | 9.10% | -92.00% | 123.21% | 374.87% |
| Cash from Operations | 24.87% | 24.81% | 11.35% | 13.42% | 21.15% |
| Capital Expenditure | -- | -- | -1,000.00% | 86.76% | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -6.70% | -32.62% | -14.79% | 28.72% | -16.21% |
| Cash from Investing | -6.70% | -32.66% | -14.83% | 29.54% | -7.48% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -37.50% | -- | -20.34% | -100.00% | -85.34% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -2,366.07% | -- | -20.34% | -100.00% | -85.34% |
| Foreign Exchange rate Adjustments | 966.67% | 171.43% | -297.37% | 169.57% | 160.00% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 44.60% | -92.89% | -23.39% | 508.57% | 40.70% |